American biotechnology company in Boston, Massachusetts, founded in 2017 and listed on the Nasdaq, which works on precision cancer medicines. Uses functional genomics and CRISPR based screening to find synthetic lethal targets in tumours with defined genetic defects, and develops small molecule inhibitors from that work, with programmes including a PRMT5 inhibitor for MTAP deleted cancers and a USP1 inhibitor for tumours with homologous recombination deficiency, running its own discovery laboratories and clinical development.
No hay comentarios disponibles.
Deja tu valoración & comentario